Q2 2023 results highlights

1. Q2 2023 results
Paul Hudson
Chief Executive Officer, Sanofi
“We delivered another solid quarter of growth and
are excited by the momentum of our RD pipeline,
with a strong flow of positive readouts and regulatory
achievements that match our best-in-class ambitions.”
Q2 2023 company sales
€9,965m (+3.3% at constant exchange rates, -1.5% on a reported basis)
Q2 2023 business earnings per share
€1.74 (+8.1% at constant exchange rates, +0.6% on a reported basis)
Sales by global business unit
Specialty Care
€4,403m
Vaccines
€1,223m
General Medicines
€3,114m
Consumer Healthcare
€1,225m

2. Sales by geography
US
€3,919m
Europe
€2,458m
Rest of the World
€3,588m
Key RD milestones
Respiratorysyncytial
virus (RSV):
US FDA approves
our RSV prevention
for newborns
and infants.
Chronic obstructivepulmonary disease(COPD):
Positivephase 3 datafor one of our
innovativebiologics.
Atopic dermatitis:
Positive toplinephase 2b dataof novelinvestigational
anti-0X40-ligandmonoclonalantibody.
Multiple sclerosis:
Positive
phase 2b datafor our novelanti-CD40Lantibody.
For further information on Q2 2023 results and definitions of financial indicators,
please refer to the press release issued on July 28, 2023 at: www.sanofi.com/en/investors